SUZHOU, China, and ROCKVILLE, MD, April 27, 2022 /PRNewswire/ — Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that updated results from seven studies involving the company’s five novel drug candidates will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. The company will present clinical trials involving the third-generation tyrosine kinase inhibitor (TKI) olverembatinib (HQP1351); as well as the following investigational agents: (1) Bcl-2 inhibitor lisaftoclax (APG-2575); (2) MDM-p53 inhibitor alrizomadlin (APG-115); (3) ALK inhibitor APG-2449; and (4) dual Bcl-2/Bcl-xL inhibitor pelcitoclax (APG-1252).
The ASCO Annual Meeting showcases the most cutting-edge research in clinical oncology and state-of-the-art advanced cancer therapies and is the world’s most influential and prominent scientific gathering of the clinical oncology community. This year’s ASCO Annual Meeting will take place both online and in-person (McCormick Place; Chicago, IL) on June 3–7, 2022.
“This is the fifth consecutive year in which Ascentage-sponsored clinical results have been selected for presentations at the ASCO Annual Meeting,” said Dr. Yifan Zhai, Chief Medical Officer. “We are pleased to be offered a further opportunity to showcase our company’s progress on multiple clinical trials and demonstrate our ample capabilities in global innovation and R&D,” she said.
“In addition to the updated results on lisaftoclax and alrizomadlin, two key drug candidates in our apoptosis-targeted pipeline, we will also release the first-in-human data of APG-2449, a promising drug candidate with potential as the first China-developed third-generation ALK inhibitor,” according to Dr. Zhai.
“We also look forward to disseminating new clinical data on recently approved third-generation TKI olverembatinib in patients with gastrointestinal…
